Forge spin­off Black­smith Med­i­cines merges back in­to com­pa­ny two years af­ter launch, but de­tails are slim

Black­smith Med­i­cines and Forge Ther­a­peu­tics an­nounced Mon­day that the com­pa­nies are merg­ing on­ly a year af­ter Black­smith launched as a spin­out of Forge, but there is lit­tle in­for­ma­tion pro­vid­ed on the uni­fi­ca­tion.

The fo­cus will be on in­fec­tion and on­col­o­gy re­search to de­vel­op drugs to tar­get met­al­loen­zymes, or en­zyme pro­teins that con­tain a met­al ion like mag­ne­sium, zinc, iron, man­ganese, cal­ci­um, cobalt or cop­per and per­form a wide range of func­tions in the body from mi­to­chon­dr­i­al func­tion to ni­tric ox­ide pro­duc­tion. Met­al­loen­zymes ac­count for over 30% of all known en­zymes across all species.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER